MYLERAN Drug Patent Profile
✉ Email this page to a colleague
When do Myleran patents expire, and what generic alternatives are available?
Myleran is a drug marketed by Waylis Therap and is included in one NDA.
The generic ingredient in MYLERAN is busulfan. There are ten drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the busulfan profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Myleran
A generic version of MYLERAN was approved as busulfan by PHARMASCIENCE INC on March 24th, 2017.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MYLERAN?
- What are the global sales for MYLERAN?
- What is Average Wholesale Price for MYLERAN?
Summary for MYLERAN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 106 |
| Clinical Trials: | 93 |
| Patent Applications: | 5,836 |
| Drug Prices: | Drug price information for MYLERAN |
| What excipients (inactive ingredients) are in MYLERAN? | MYLERAN excipients list |
| DailyMed Link: | MYLERAN at DailyMed |
Recent Clinical Trials for MYLERAN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| GlycoMimetics Incorporated | Phase 1/Phase 2 |
| John Horan, MD | Phase 1/Phase 2 |
| Baptist Health South Florida | Phase 1/Phase 2 |
Pharmacology for MYLERAN
| Drug Class | Alkylating Drug |
| Mechanism of Action | Alkylating Activity |
US Patents and Regulatory Information for MYLERAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Waylis Therap | MYLERAN | busulfan | TABLET;ORAL | 009386-001 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for MYLERAN
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Pierre Fabre Medicament | Busilvex | busulfan | EMEA/H/C/000472 Busilvex followed by cyclophosphamide (BuCy2) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation (HPCT) in adult patients when the combination is considered the best available option.Busilvex following fludarabine (FB) is indicated as conditioning treatment prior to haematopoietic progenitor cell transplantation (HPCT) in adult patients who are candidates for a reduced-intensity conditioning (RIC) regimen.Busilvex followed by cyclophosphamide (BuCy4) or melphalan (BuMel) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation in paediatric patients. |
Withdrawn | no | no | no | 2003-07-09 | |
| Fresenius Kabi Deutschland GmbH | Busulfan Fresenius Kabi | busulfan | EMEA/H/C/002806 Busulfan Fresenius Kabi followed by cyclophosphamide (BuCy2) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation (HPCT) in adult patients when the combination is considered the best available option.Busulfan Fresenius Kabi followed by cyclophosphamide (BuCy4) or melphalan (BuMel) is indicated as conditioning treatment prior to conventional haematopoietic progenitor cell transplantation in paediatric patients. |
Authorised | yes | no | no | 2014-09-22 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
